JAMA 11月15日 SURMOUNT-ADOLESCENTS 试验:160名青少年72周 BMI 平均降18.5%,安慰剂组升0.5%

《JAMA》11月15日在线发表三期随机临床试验 SURMOUNT-ADOLESCENTS 的结果,评估每周一次皮下注射替尔泊肽对青少年肥胖的疗效与安全性。试验在 加拿大、捷克、以色列、意大利、波兰与美国的31个中心开展,时间为2023年10月16日至2026年6月2日。
共有160名12岁至未满18岁的青少年被随机分组,其中109人接受替尔泊肽、51人接受安慰剂,另加生活方式辅导。入组者为肥胖,或超重且至少有一项肥胖相关并发症。基线时平均年龄14.6岁,女性占61.9%,平均体重109.7公斤,平均身体质量指数(BMI)为38.6。替尔泊肽每4周递增剂量,至5、10或15毫克的最大耐受剂量。
第72周的主要结局显示,替尔泊肽组 BMI 平均下降18.5%,安慰剂组平均上升0.5%,估计治疗差异为负19.0个百分点。替尔泊肽组79.6%的人 BMI 至少下降5%,安慰剂组为28.5%。
论文由 Aaron S. Kelly 等人撰写,试验由礼来公司资助并在 ClinicalTrials.gov 注册(NCT06075667)。《JAMA》同期研究概要指出,仍需要更长期的随访数据。本稿只报道试验结果,不构成对任何个体的用药建议。
图中是替尔泊肽的化学结构式,本试验评估的正是该药每周一次注射的方案。
JAMA SURMOUNT-ADOLESCENTS Trial on November 15: Among 160 Adolescents, BMI Fell a Mean 18.5 Percent at 72 Weeks on Tirzepatide Versus a 0.5 Percent Rise on Placebo
JAMA published online on November 15 the results of SURMOUNT-ADOLESCENTS, a phase 3 randomized clinical trial of once-weekly subcutaneous tirzepatide in adolescents with obesity. The trial was conducted at 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland and the United States from October 16, 2023, to June 2, 2026.
A total of 160 adolescents aged 12 years to younger than 18 years were randomized, 109 to tirzepatide and 51 to placebo, in addition to lifestyle counseling. Participants had obesity, or overweight with at least one obesity-related complication. At baseline the mean age was 14.6 years, 61.9 percent were female, mean body weight was 109.7 kg and mean body mass index (BMI) was 38.6. Tirzepatide was escalated every four weeks to a maximum tolerated dose of 5, 10 or 15 mg.
At week 72, the primary outcome showed a mean BMI reduction of 18.5 percent with tirzepatide, compared with a 0.5 percent increase with placebo, an estimated treatment difference of minus 19.0 percentage points. In the tirzepatide group, 79.6 percent achieved a BMI reduction of at least 5 percent, compared with 28.5 percent on placebo.
The paper, by Aaron S. Kelly and colleagues, was funded by Eli Lilly and registered on ClinicalTrials.gov as NCT06075667. JAMA's research summary notes that longer-term follow-up data are still needed. This report presents the trial results only and is not advice on medication for any individual.
来源:《JAMA》
发布:GSM·美国(发布链接)
图片来源:Wikimedia Commons, File:Tirzepatide structure.svg — Author: Vaccinationist. Licensing: Public domain.
GSM Global · 本篇英文版 English edition of this story

